Member Info for Kaneonaim

The overall goal of this U01 project (CA176110) is to develop and validate both standard and novel perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI) biomarkers for evaluation of brain tumors and their response to therapies. Two PWI methods will be characterized for clinical trials. The first more wide-spread DSC (dynamic susceptibility contrast) approach provides tumor rCBV (relative cerebral blood volume) measurements obtained after a pre-load of contrast agent and corrected for confounding contrast agent leakage effects. The second approach, while less-proven has high-potential to become the most comprehensive perfusion solution. It consists of using a spiral perfusion imaging method with consecutive echoes (SPICE), which enables the simultaneous collection of both DSC (dynamic susceptibility contrast) and DCE (dynamic contrast enhanced) perfusion data using only a single dose of contrast agent and incorporates comprehensive correction for leakage effects. In addition, the team will continue to explore the potential of DWI methods for the evaluation of treatment response, specifically by computing changes in the apparent diffusion coefficient (ADC) across time and creating functional diffusion maps (fDM) within non-contrast-agent-enhancing regions.

While both PWI and DWI have demonstrated great promise for treatment monitoring, studies defining their test-retest repeatability, necessary for use of these techniques in clinical trials, are lacking, and thus represent the focus of Aim 1. In addition, early results suggest that hybrid PWI/DWI maps will likely provide the most complete assessment of treatment response, a hypothesis that will be tested in Aim 2. Finally, in order to make the optimized PWI/DWI technology and workflow available in a robust and cost-effective manner for clinical trials and standard practice, Aim 3 involves the development of a commercial integrated image analysis platform for use in large-scale multi-center clinical trials. This aim is being accomplished in collaboration with Imaging Biometrics LLC, co-investigators on the U01.

Point 7 of the update from January doesn’t get much discussion which I find odd as it goes into detail about the FIRST grant we received (yes we have 2) here it is

7. The Company is fulfilling the work outlined in its two funded grants collaborating with MCW and the Barrow Neurological Institute ("BNI"). Both grants are "industrial-academic partnerships", aimed at commercialising technologies and incorporating them into routine clinical use, and each grant is entering into the second year of its five-year term. The grant in collaboration with MCW is the second such award as part of the Quantitative Imaging Network ("QIN"). The QIN is an initiative sponsored by the US National Cancer Institute ("NCI") promoting research, development, and clinical validation of quantitative imaging tools and methods for the measurement or prediction of tumour response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. The grant in collaboration with BNI includes working with major scanner vendors (GE, Siemens, and Philips) to harmonise the way perfusion MRI data is collected and post-processed. The involvement of the major scanner vendors is exciting and very positive, and the Company looks forward to their continued collaboration and support.

Here’s a link to Kathleen Schmainda overall goals of this project

https://imaging.cancer.gov/programs_resources/specialized_initiatives/qin/qinsites/medical_college_of_wisconsin.htm

The Quantitative Imaging Network (QIN) promotes research, development and clinical validation of quantitative imaging tools and methods for the measurement or prediction of tumor response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Projects include the development and adaptation/implementation of quantitative imaging methods, imaging protocols, and software solutions/tools (used with existing commercial imaging platforms and instrumentation) and application of these methods in current and planned clinical therapy trials. The research projects focus on image-derived quantitative measurements of responses to drugs and/or radiation therapy during clinical trials or standard of care. To achieve the goals of the QIN, multidisciplinary teams which include oncologists as well as clinical and basic imaging scientists are required. The involvement of industrial partners in the development and adaptation/implementation of quantitative imaging methods to aid cancer therapies are encouraged.

At least get your facts right before you make yourself look silly!!!

“The share price now is below it was BEFORE FDA and CE Mark”

Not true!! On the morning of fda announcement the shares were priced at 4.9p a couple of weeks before that they were even cheaper at 3.8 and a couple of months before that they were 2.4 you as well as everyone else had the opportunity to get in then YOU didn’t You chose to get in after maybe experienced a bit of FOMO no one’s fault but yours

Trevor has every right like everyone else to sell his holding it’s the name of the game if you don’t like it then stick to the casinos!!!

Bad news

Anglo Asian Mining plc
Transaction with Conroy Gold

Anglo Asian Mining PLC ("AAZ" or the "Company"), the AIM listed gold, copper and silver producer focused in Azerbaijan, has today terminated discussions with Conroy Gold and Natural Resources plc ("Conroy") in respect of the previously announced proposed joint venture agreement. Details of the heads of terms signed on a proposed joint venture with Conroy were announced by the Company on 21 July 2020.

Canaccord Charlie Sharp

I’ve previously seen this on the company website but there’s no link and when I’ve searched in the past can’t find anything it’s probably not for us Muggles

Wednesday broker round-up

https://www.sharecast.com/news/broker-recommendations/wednesday-broker-round-up--7823232.html

Just looked as I thought Hargreaves showing on the list is new and remembered I posted the list back in January and was correct they weren’t on their!!

NEW?

Here’s my post from January

RE: Well I didn't expect this...17 Jan 2021 14:35
Not sure of their average but they hold a fair amount !
Shareholder Number of Ordinary Shares Percentage held (%)
Bybrook Capital 206,438,717 29.68%
Premier Miton Investors 105,000,000 15.09%
Slater Investments 82,800,000 11.90%
Lombard Odier 55,000,000 7.91%

No Hargreaves!

Major Shareholders

As at 29/01/21, the major shareholders are as follows:

Shareholder Number of Ordinary Shares Percentage held (%)
Bybrook Capital 206,438,717 29.49
Premier Miton Investors 105,000,000 15.00
Slater Investments 82,800,000 11.83
Lombard Odier 60,510,601 8.64
Hargreaves Lansdown 36,134,757 5.16

If they want their employee options then imo they need 14000 boe by July!!

The Options will vest as follows:

· One-third immediately;

· One-third if July 2021 production exits at or above 9,000 boepd; and

· 100 per cent. upon the addition of 5,000 boepd or 25 MMboe 2P reserves.



Following this announcement there is no change to the Company's issued ordinary shares (700,054,815 ordinary shares of £0.0001 each)

Helping a friend build his swimming pool absolutely feked!!

Another good day!!! 8p 16:45

Tony life is too short to worry about what others say or do just enjoy it!!!!

Don’t want to sound too rampy ff lol!!

Finished 185%!! Should be a good day tomorrow

276% lol!!! Boom boom

257%

233% boom

204%

185%

Lol!!!!

It’s only 147% now

Back to 128% up

Tony you have been negative all day you really do sound as if you’ve sold and regret it lol!!!

https://money.tmx.com/en/quote/ITE